Oxford Brain Diagnostics looks for collaboration partners for neurodegeneration

We are on a mission to change the way the world thinks about brain health. Our novel technology assesses brain health based on changes in the cellular structure. We enable more efficient drug development and personalised patient care.

Oxford Brain Diagnostics are looking for interested clinicians dealing with dementia who would like to learn about a  new approach to MRI-based diagnosis, which can predict transition from MCI to Alzheimer’s Disease, and has  received FDA breakthrough device designation (neurologists, psychiatrists, radiologists, focus on US). 

We are developing a new software tool for the interpretation of MRI images, pulling together current volumetric  methods (cortical volume, cortical thickness, hippocampal measures) with our new measure which analyses changes  in the brain at a cellular level. Our goal is to bring an innovative diagnostics tool which will positively enable better  patient care, more certainty in diagnosis, differential diagnosis of dementia, and the possibility to accurately track  decline (www.oxfordbraindiagnostics.com) 

Some recent papers published  

Also see https://oxfordbraindiagnostics.com/06-publications.html 

Cortical diffusivity investigation in posterior cortical atrophy and typical Alzheimer’s disease. Mario Torso (et al) – Journal of Neurology (2020) Journal of Neurology 

Using diffusion tensor imaging to detect cortical changes in fronto-temporal dementia subtypes. M. Torso (et al) – Scientific Reports, A Nature research Journal 

Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes  following blast exposure. Dara L. Dickstein (et al) – Molecular Psychiatry  

Relating diffusion tensor imaging measurements to microstructural quantities in the cerebral cortex in multiple  sclerosis. Rebecca McKavanagh (et al) – Human Brain Mapping Journal

Discover more about Oxford Brain Diagnostics:

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.